E ndothelin-1 (ET)-1, a 21-aa peptide produced by endothelial and other cells, is one of the most potent vasoconstrictors. 1,2 Plasma ET-1 is increased in patients with essential hypertension and in hypertension associated with systemic disorders, in atherosclerosis and heart failure, as well as in other cardiovascular and metabolic disorders, and in chronic kidney disease. 3 ET-1 plays a role in the development of hypertension by causing vascular damage and inflammation. 4, 5 Transgenic mice overexpressing ET-1 specifically in endothelial cells (eET-1) present endothelial dysfunction and vascular remodeling, oxidative stress, and inflammation. 6, 7 The immune system plays a role in hypertension and vascular injury. 8-10 The innate immune system is involved in angiotensin (Ang) II, deoxycorticosterone acetate (DOCA)/ salt, and aldosterone-induced hypertension and vascular damage. [11] [12] [13] Ang II, DOCA/salt, and aldosterone infusion caused an increase in vascular monocyte/macrophage infiltration. Ang II and DOCA/salt-induced hypertension and vascular remodeling, oxidative stress, and inflammation were blunted in a model with reduced monocytes/ macrophages, the osteopetrotic (Op) mouse, which is deficient in macrophage colony stimulating factor (CSF) 11,12 because of a thymidine (T) insertion in the coding region of the colony stimulating factor (Csf1) gene that generates a stop codon 21 bp downstream. 14 Similarly, aldosterone-induced endothelial dysfunction and vascular oxidative stress were decreased in Csf1 Op/+ mice. 13 The innate immune system could play a role in ET-1-induced vascular injury, because the inflammation observed in eET-1 is characterized by an increase in vascular monocyte/macrophage infiltration. 7 However, this remains to be demonstrated.
Methods
Additional Materials and Methods are mentioned in the online-only Data Supplement.
Animals
The study was approved by the Animal Care Committee of the Lady Davis Institute for Medical Research and McGill University, followed recommendations of the Canadian Council for Animal Care, and was in agreement with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health. We used 4-to 6-month-old male mice with endothelium-specific ET-1 overexpression (eET-1), reduction in CSF1 (Csf1 Op/+ ), or both (eET-1/Csf1 Op/+ ), and their wild-type (WT) littermate control mice. Mice were generated by crossing heterozygous Csf1 Op/+ mice (C57BL/6) [11] [12] [13] with eET-1 transgenic mice overexpressing the human ET-1 driven by the Tie-2 promoter/enhancer-conferring endothelialspecific expression (C57BL/6). 6 Mice were genotyped for the presence or absence of eET-1 by polymerase chain reaction and for Op mutation within Csf1 gene by polymerase chain reaction followed by BstXI restriction digestion ( Figure S1 in the online-only Data Supplement). Systolic blood pressure was measured by tail-cuff method using MC4000 blood pressure analysis system (Hatteras Instruments, Cary, NC). Mice were anesthetized with 3% isoflurane mixed with O 2 at 1 L/mL, depth of anesthesia was confirmed by rear foot squeezing, blood was collected by cardiac puncture for plasma ET-1 quantification, and mesenteric arcade was dissected for determination of mesenteric artery endothelial function and vascular structure and NADPH oxidase activity. Aorta was isolated to assay reactive oxygen species production and monocyte/macrophage infiltration.
Statistical Analysis
Data are presented as means±SEM. Comparisons were made by 1-way ANOVA, followed by a Student-Newman-Keuls post hoc test. A 2-way ANOVA was used to compare the contractile response to ET-1 before and after BQ123. A value of P<0.05 was considered significant.
Results

Physiological Parameters
Increased expression of ET-1 and reduction in CSF1 did not affect body weight, systolic blood pressure, tibia length, and weight of the heart or kidneys (Table) .
Endothelium-Dependent and Endothelium-Independent Responses
Endothelium-dependent relaxation responses to acetylcholine were not altered by overexpression of ET-1 and reduction in CSF1 ( Figure 1A) . In presence of the NO synthase inhibitor L-NAME, acetylcholine-induced relaxation was reduced to ≈41% in WT and eET-1 mice, whereas it was reduced to ≈75% in Csf1 Op/+ and eET-1/Csf1 Op/+ mice ( Figure 1B) . These results suggest that reduction in CSF1 altered the mechanisms mediating acetylcholine-induced relaxation. Endotheliumindependent relaxation to the NO donor sodium nitroprusside was unaltered by overexpression of ET-1 and CSF1 deficiency ( Figure 1C ).
ET-1 Overexpression-Induced Vascular Remodeling Was Prevented by CSF1 Deficiency
Increased expression of ET-1 caused hypertrophic remodeling of mesenteric arteries. Media:lumen ratio and media crosssectional area of mesenteric resistance arteries were ≈1.5fold greater in eET-1 mice compared with WT mice. This was prevented by CSF1 reduction ( Figure 1D and 1E). The stress-strain curve was unaffected by increased ET-1 expression ( Figure 1F ). As previously observed, 13 CSF1 deficiency reduced vascular stiffness of mesenteric resistance arteries as demonstrated by a rightward shift in the stress-strain curve compared with WT mice.
ET-1 Overexpression-Induced Reduction in Contractile Response to ET-1 Was Blunted by CSF1 Reduction
eET-1 mice exhibited a reduced contractile response to ET-1 compared with WT mice, change that was blunted by reduced CSF1 (Figure 2A ). The ET A receptor blocker BQ123 reduced maximal contractile responses to ET-1 to a similar extent in all groups ( Figure 2B ).
CSF1 Deficiency Prevented ET-1 Overexpression-Induced Oxidative Stress
Increased expression of ET-1 induced a 5-fold increase in reactive oxygen species generation in the aorta of eET-1 mice compared with WT mice, which was prevented by CSF1 deficiency ( Figure 3A and Figure S2 ). ET-1 caused a 7-fold elevation in NADPH oxidase activity in mesenteric arteries of eET-1 mice compared with WT mice, which was prevented by reduced CSF1 ( Figure 3B ).
CSF1 Reduction Prevented ET-1 Overexpression-Induced Inflammation
Monocyte/macrophage infiltration increased 2.5-fold in aorta of eET-1 mice compared with WT mice (Figure 4 and Figure Body and tissue weights and tibia length were determined in WT, eET-1, Csf1 Op/+ , and eET-1/Csf1 Op/+ mice. Values are means±SEM, n = 8 to 10. Csf indicates colony stimulating factor; eET-1, endothelium-specific endothelin-1 overexpression; SBP, systolic blood pressure; and WT, wild-type.
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). Most of the increase in monocyte/macrophage infiltration was found in the adventitia and perivascular fat. As previously observed, 13 Csf1 Op/+ mice presented a 60% reduction in monocyte/macrophage infiltration compared with WT mice. Monocyte/macrophage infiltration was not different in eET-1/ Csf1 Op/+ mice compared with Csf1 Op/+ mice.
CSF1 Reduction Does Not Alter ET-1 Overexpression
As we previously described, 6 plasma ET-1 level was increased 9-fold in eET-1 mice compared with WT mice ( Figure 5 ). Basal or increased plasma ET-1 levels were not affected by Csf1 haploinsufficiency. Plasma ET-1 level in Csf1 Op/+ was unchanged relative to WT mice and was increased 16-fold in eET-1/Csf1 Op/+ mice compared with Csf1 Op/+ mice. Thus, the reduced vascular injury observed in eET-1/Csf1 Op/+ mice is not attributable to changes or a decrease in ET-1 overexpression.
Discussion
During the past few years, it has become increasingly apparent that not only is inflammation a mechanism participating in vascular injury associated with high blood pressure but also that the immune system is a major contributor to the process of inflammation in many cardiovascular conditions. 8, 9, 15 Both the innate and the adaptive immune responses have been implicated in cardiovascular disease, particularly in hypertensive renal pathology 16 and, more recently, in vascular and heart disease. 12, [17] [18] [19] Indeed, it was previously showed that the innate immune system is involved in Ang II and DOCA/salt-induced hypertension and vascular injury and in aldosterone-induced vascular damage in a blood pressure-independent fashion. [11] [12] [13] Other investigators have as well more recently confirmed a role for macrophages/monocytes in Ang II-induced actions on blood pressure and the vasculature. 19 Thus, although different forms of hypertension are associated with a role of immune mechanisms, whether all experimental models of hypertension have an immune component is unknown. The present study demonstrates for the first time that ET-1-induced vascular hypertrophic remodeling and oxidative stress are prevented by CSF1 deficiency, which leads to an impaired monocyte and macrophage production and maturation, 20 thus demonstrating a role of the latter in this particular model. CSF1 deficiency leads also to deficiency in osteoclast production and differentiation in the bone. However, there is no reason to believe that osteoclasts play a role in ET-1-induced vascular damage in the present model. Enhancement of ET-1 expression in eET-1 mice was associated with a decreased contractile response to ET-1, hypertrophic remodeling and vascular oxidative stress, and inflammation. 6, 7 However, increased ET-1 expression did not result in endothelial dysfunction. The latter phenotype could be attributable to additional backcrossing of the mice in the C57BL/6 background or to an accidental selection for mice resistance to ET-1-induced endothelial dysfunction. It is presently unclear why endothelial function was unaffected by the increase in oxidative stress in mesenteric arteries. It does not seem that a NO synthase-independent mechanism could have developed in mesenteric arteries of this particular group of eET-1 mice because relaxation was inhibited by the NO synthase inhibitor L-NAME to the same extent as in WT mice ( Figure 1A and 1B) . As previously demonstrated using telemetry, systolic blood pressure of eET-1 mice was normal. 6 Interestingly, these results suggest that the mechanisms causing vascular injury in this paradigm do not require endothelial dysfunction or blood pressure elevation.
The mechanisms behind the development of essential hypertension are unclear and probably complex. ET-1 is probably involved in the development of hypertension. [3] [4] [5] It is possible that an increase in ET-1 is not sufficient to cause hypertension. Additional mechanisms not present in this model, such as compromised kidney function or endothelial dysfunction, or activation of other pathophysiological pathways, may be necessary to cause a blood pressure rise. It is also possible that compensatory mechanisms counteracting the contractile effects of ET-1 have developed in endothelial cells. The kidneys, which play a major role in long-term control of blood pressure, 21 could counteract the increase in peripheral resistance because of ET-1-induced vascular remodeling. Additional studies are required to clarify the pathophysiological role of ET-1 in the development of hypertension in both experimental models and in humans.
The relaxation response to acetylcholine of Csf1 Op/+ mice with reduced CSF1 was less affected by L-NAME compared with wild-type mice, which indicates the presence of NO synthase-independent relaxation mechanisms. The decrease in monocyte/macrophage infiltration in the adventitia could play a role in the change in the relaxation mechanisms in Csf1 Op/+ mice. This was not found in previous studies using the Csf1 Op/+ mice [11] [12] [13] and could also result from backcrossing of the mice in the C57BL/6 background.
WT littermate mice were used to control for the gain in ET-1 expression or deficiency in CSF1. WT littermate mice also controlled for the background and environment. This was possible because they are littermates of eET-1 and Csf1 Op/+ mice. All the mice, including the eET-1/Csf1 Op/+ mice, were produced by mating eET-1 mice with Csf1 Op/+ mice. Both eET-1 and Csf1 Op/+ mice have the same C57BL/6 background. Csf1 Op/+ mice were used to control for gain in ET-1 expression in the presence of CSF1 deficiency. Csf1 Op/+ mice are littermates of eET-1/Csf1 Op/+ mice and control also for the background and environment.
Using Csf1 Op/Op and Csf1 Op/+ mice, we had concluded that the innate immune system plays a role in Ang II, DOCA/salt, and aldosterone-induced vascular injury. [11] [12] [13] Deficiency of CSF1 prevented Ang II and DOCA/salt-induced endothelial dysfunction, hypertrophic remodeling, oxidative stress and inflammation, and aldosterone-induced endothelial dysfunction and oxidative stress. In this study, reduction in CSF1 blunted ET-1-induced hypertrophic remodeling and oxidative stress. The common finding between all these studies is that deficiency or reduction in CSF1 decreased vascular monocyte/ macrophage infiltration and blunted the oxidative stress response to Ang II, DOCA/salt, aldosterone, and ET-1. These data support a role for monocytes/macrophages and the innate immune system in the development of vascular oxidative stress, and its contribution to vascular injury. However, what triggers the innate immune system response remains to be clarified.
The adventitia is a complex structure of blood vessels, constituted by an extracellular matrix scaffold containing fibroblasts, blood and lymphatic vessels (and, thus, endothelial cells), nerves, progenitor cells, and immune cells, including macrophages. 22 Perivascular fat is closely associated to the adventitia. Overexpression of ET-1 in endothelial cells caused an increase in monocyte/macrophage infiltration in the adventitia and associated perivascular fat, which is similar to findings in mice infused with Ang II or aldosterone. 23, 24 However, the mechanisms by which Ang II, aldosterone, or ET-1 cause an increase in immune cell infiltration remain unknown. Vascular inflammation could be initiated and perpetuated in the adventitia, according to the outside-in hypothesis. 22 Increased expression of ET-1 in endothelium or within the adventitia could act in paracrine fashion directly on monocytes or macrophages or via other cells, such as the smooth muscle cells. In this study and previously, we found that a deficiency in CSF1 impaired monocyte/macrophage infiltration induced by ET-1, Ang II, and DOCA/salt in rodents, the latter a hypertensive model with an important ET-1-dependent component. CSF1 is a critical factor for monocyte production, monocyte to macrophage differentiation, and macrophage maturation. 20 Op mice have a deficiency in peripheral blood monocytes and in macrophages in tissues, 20, 25 and in addition, residual macrophages in tissues of Op mice present an immature phenotype. 20 Furthermore, CSF1 is expressed locally in endothelial cells, smooth muscle cells, monocytes, and macrophages. 26 Therefore, it can be expected that a deficiency in CSF1 will have a profound effect on the bone marrow monocyte production and, at the vascular level, on monocyte to macrophage differentiation and macrophage maturation, resulting in blunting of vascular inflammation. The adaptive immune system has also been implicated in Ang II, DOCA/salt, and aldosterone-induced vascular damage. 17, 23, 24 Whether it is involved in ET-1-induced vascular injury is unknown. In addition, it has not been determined whether the activation of the innate immune system precedes or accompanies activation of the adaptive immune response. However, it is reasonable to think that activation of innate immunity stimulates the adaptive immunity because macrophages could act as antigen-presenting cells to T lymphocytes.
ET-1 and the innate immune system could play a role in the development of vascular injury in patients with hypertension. Parissis et al 27 have observed a significant correlation between elevated plasma ET-1 and peripheral monocyte-related inflammatory markers in patients with hypertension with or without hypercholesterolemia. Further work is required to demonstrate this mechanism in humans.
In conclusion, by crossing mice that overexpress ET-1 in the endothelium with mice with deficient macrophages as a consequence of a mutation in the Csf1 gene, we have extended the findings of the role of the innate immune system to a rodent model of vascular injury associated with ET-1 overexpression. These results unambiguously implicate innate immunity in inflammatory responses to ET-1.
Perspectives
Monocytes/macrophages and, therefore, the innate immune system play a role in vascular injury in different conditions, leading to the development or maintenance of hypertension by increasing oxidative stress. These include the actions of Ang II and mineralocorticoids, to which ET-1 is now added. Additional work is required to reveal the mechanism of activation of the innate immune system in this paradigm. Discovery of mechanisms involved in the activation of the innate immunity could allow discovery of novel therapeutic targets for the treatment of hypertension.
